Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people
Julia Hippisley–Cox, Pui San Tan, Carol Coupland
Topics & Concepts
MedicineAngiotensin Receptor BlockersCoronavirus disease 2019 (COVID-19)CohortInternal medicineCohort studySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)DiseaseAngiotensin-converting enzyme2019-20 coronavirus outbreakPharmacologyVirologyInfectious disease (medical specialty)OutbreakBlood pressureLong-Term Effects of COVID-19COVID-19 Clinical Research StudiesHeart Rate Variability and Autonomic Control